AKD’s Top 3 Pharma Picks For 2026

3. Highnoon Laboratories Limited (HINOON)

Highnoon Laboratories Limited remains one of the strongest pharmaceutical growth stories heading into 2026 due to its premium margin profile, export expansion, aggressive capacity investments, and strong dividend generation.

Structural Margins Continue To Lead The Sector

The company maintains one of the strongest profitability profiles in the industry, with a five-year average gross margin of nearly 50%. During the first nine months of 2025, margins improved further to 55%, supported by the company’s heavy focus on chronic therapies, including cardiology and respiratory care. Chronic products currently account for nearly 47% of the portfolio, providing recurring demand and stronger pricing power. More than half of the company’s portfolio also falls within the deregulated non-essential medicine category, allowing better price pass-through capability.

📢 Announcement: You can now access our services and similar analyses by opening an account with us via JS Global

Don't miss:

• Top 5 Analyst Questions From Lucky Core Industries (LCI) Corporate Briefing
• 5 Reasons Why MEBL Could Continue Rising Despite a Growth Slowdown
• AKD Predicts PSO Could Double From Here

Project FORCE Is A Major 2026 Expansion Driver

One of the company’s most important strategic developments is “Project FORCE,” a greenfield manufacturing facility near Lahore. Construction officially began in January 2026. Since the facility is located inside a Special Economic Zone, management expects the project to benefit from a 10-year tax exemption, structurally improving long-term profitability. The project is also designed to support international regulatory compliance and future export expansion.

Corporate Expansion Strategy Continues

Management approved the evaluation of a potential acquisition target during February 2026 to strengthen the company’s product portfolio and operational scale. The company also signed an MoU with Beximco Pharmaceuticals for the marketing and distribution of specialized products focused on diabetes and cardiovascular care.

Dividend And Export Profile Remain Strong

Highnoon continues to maintain one of the sector’s strongest shareholder payout profiles, supported by healthy profitability and low leverage. The company’s debt-to-equity ratio stands at only 0.06x, providing flexibility for future expansion financing if required. Exports have also remained a major growth area, with the company delivering a 24% export CAGR over the last decade while maintaining operations across markets including the UAE, France, and Kenya.

Conclusion

📢 Announcement: We're on WhatsApp – Join Us There! 

Pakistan’s pharmaceutical sector is increasingly being shaped by companies with strong brands, pricing flexibility, export expansion, and structurally improving margins. The latest corporate briefing data for 2026 shows that leading players are no longer relying solely on traditional medicine sales but are also investing aggressively in manufacturing upgrades, wellness products, exports, and high-margin chronic therapies. Highnoon Laboratories Limited continues to stand out through its premium margin profile, export momentum, and Project FORCE expansion strategy. Haleon Pakistan Limited remains supported by dominant household brands, manufacturing localization, and strong return metrics. Meanwhile, GlaxoSmithKline Pakistan is benefiting from margin recovery, a stronger product mix, and one of the strongest balance sheets in the sector. Based on the latest operational updates and 2026 strategic outlooks, these companies remain among the most closely watched pharmaceutical names on the Pakistan Stock Exchange for investors seeking a combination of earnings stability, structural growth, and long-term sector leadership.

⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →